Author

R. Mazitschek

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Cancer Biology· 1 Microbiology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:drug response / drug discovery· 3 Organism:human· 2 Assay:proteomics· 2 Research Focus:cell type annotation· 1 Research Focus:host-pathogen & immune response· 1 Organism:plant (other)· 1

Frequent Co-Authors

N. C. Payne· 2 shared A. E. Nibbs· 1 shared A. K. Lukens· 1 shared A. Kirov· 1 shared B. A. Tannous· 1 shared B. Tannous· 1 shared C. C. da Hora· 1 shared c. E. badr· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 14 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBiochemistry

N. C. Payne

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

The Cyclimids: Degron-inspired cereblon binders for targeted protein degradation

S. Ichikawa, N. C. Payne, W. Xu, C.-F. Chang, N. Vallavoju, S. Frome, H. A. Flaxman, R. Mazitschek, C. M. Woo

This study introduces cyclimids, degrons derived from CRBN, which show improved selectivity and potency in targeted protein degradation by forming ternary complexes with CRBN and substrates.

bioRxiv · Apr 22, 2023Biochemistry

Collateral sensitivity as a strategy to suppress resistance emergence: the challenge of diverse evolutionary pathways

R. E. K. Mandt, M. R. Luth, M. A. Tye, R. Mazitschek, S. Ottilie, E. A. Winzeler, M. J. Lafuente-Monasterio, F. J. Gamo, D. F. Wirth, A. K. Lukens

This study investigates collateral sensitivity between DHODH inhibitors to suppress malaria resistance, finding that cross-resistant mutants can emerge despite initial sensitivity.

bioRxiv · Apr 7, 2022Microbiology

A direct high-throughput protein quantification strategy facilitates discovery and characterization of a celastrol-derived BRD4 degrader

N. C. Payne, S. Maksoud, B. Tannous, R. Mazitschek

This paper introduces a TR-FRET-based method to quantify protein levels and measure small-molecule target engagement, validated for BRD4 degradation by celastrol.

bioRxiv · Dec 8, 2021Pharmacology & Toxicology

Obtusaquinone is a cysteine modifying compound that targets Keap1 for degradation

c. E. badr, C. C. da Hora, A. Kirov, R. Amante, E. Fitzsimons, J. W. Chen, A. E. Nibbs, I. Nakano, E. Tabet, N. Chiu, W. Haas, R. Mazitschek, B. A. Tannous

This study identifies Obtusaquinone as a cysteine-modifying compound that targets Keap1 for degradation, activating the Nrf2 pathway through proteasomal degradation.

ACS Chemical Biology · Apr 27, 2020Peer-reviewedCancer Biology